# Selection of long COVID symptoms influences prevalence estimates in a prospective cohort

3

4 <u>Authors:</u>

- 5 Elke Wynberg (MBBS, MSc)<sup>1</sup>, Godelieve J. de Bree (MD, PhD)<sup>2</sup>, Tjalling Leenstra (MD,
- 6 PhD)<sup>3</sup>, Anouk Verveen (MSc)<sup>4</sup>, Hugo D.G. van Willigen (MD)<sup>5</sup>, Menno D. de Jong (MD,
- 7 PhD)<sup>5</sup>, Maria Prins (PhD)<sup>1,5\*</sup>, and Anders Boyd (PhD)<sup>1,6\*</sup> for the RECoVERED Study Group<sup>+</sup>

# 8 Author Affiliations:

- <sup>9</sup> <sup>1</sup> Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the
- 10 Netherlands
- <sup>2</sup> Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam,
- 12 Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
- <sup>3</sup> National Institute for Public Health and the Environment (RIVM), Center for Infectious
   Disease Control (LCI), Bilthoven, Netherlands
- <sup>4</sup> Department of Medical Psychology, Amsterdam UMC, Amsterdam Public Health Research

16 Institute, University of Amsterdam, Amsterdam, the Netherlands

- <sup>5</sup> Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of
- 18 Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
- <sup>6</sup> Stichting hiv monitoring, Amsterdam, the Netherlands
- 20 Corresponding author:
- 21 Name: Elke Wynberg
- Address: Department of Infectious Diseases, Public Health Department of Amsterdam,
   Nieuwe Achtergracht 100, 1018 WT, Amsterdam, the Netherlands
- 24 Email: ewijnberg@ggd.amsterdam.nl
- 25 Telephone: +31 627991940
- 26 ORCID: 0000-0002-8245-086X
- 27
- 28 + Listed in Acknowledgments \*Authors contributed equally
- 29 Key words: Long COVID, COVID-19, symptoms
- 30 Running title: Variations of long COVID symptom selection

31 Abstract

### 32 Background:

33 Studies on long COVID differ in the selection of symptoms used to define the condition. We

- 34 aimed to assess to what extent symptom selection impacts prevalence estimates of long
- 35 COVID.

#### 36 Methods:

- 37 In a prospective cohort of patients who experienced mild to critical coronavirus disease 2019
- 38 (COVID-19), we used longitudinal data on the presence of 20 different symptoms to evaluate
- 39 changes in the prevalence of long COVID over time when altering symptom selection.

## 40 Results:

- 41 Changing symptom selection resulted in wide variation in long COVID prevalence, even
- 42 within the same study population. Long COVID prevalence at 12 months since illness onset
- 43 ranged from 39.6% (95%CI=33.4-46.2) when using a limited selection of symptoms to 80.6%
- 44 (95%Cl=74.8-85.4) when considering any reported symptom to be relevant.

#### 45 **Conclusions:**

- 46 Comparing the occurrence of long COVID is already complex due to heterogeneity in study
- 47 design and population. Disparate symptom selection may further hamper comparison of long
- 48 COVID estimates between populations. Harmonised data collection tools could be one
- 49 means to achieve greater reproducibility and comparability of results.

#### 50 Introduction

51 Commonly-used definitions of long COVID, or post-acute sequelae of COVID-19 (PASC), 52 require the presence of at least one relevant symptom for a minimum period of time [1, 2]. 53 Although most definitions stipulate that long COVID symptoms must not be linked to an 54 alternative diagnosis, the decision as to which complaints are considered relevant is left to 55 the discretion of researchers and clinicians. Notwithstanding existing heterogeneity in study 56 population and design, inconsistencies in symptom selection between studies may further 57 influence the ability to compare long COVID prevalence estimates.

58 These inconsistencies in symptom selection may arise from numerous methodological 59 differences. Some studies, for instance, choose to adopt a brief questionnaire to collect data 60 on a limited number of symptoms[3]. Other studies record the presence of over 50 distinct 61 symptoms to encompass the full spectrum of the long COVID phenotype[4], unsurprisingly reporting higher prevalence rates of long COVID than studies using less exhaustive symptom 62 63 surveys. Long COVID is also known to exhibit patterns of remitting and relapsing 64 symptoms[4]. However, correctly attributing recurrent episodes of non-specific symptoms to 65 long COVID remains a methodological challenge. Indeed, researchers may differ in their 66 choice to record prevalent (i.e., at a given moment) or persistent symptoms (i.e., those that 67 are found for two or more consecutive visits and/or from illness onset onwards) in their 68 definition of long COVID.

No studies to date have evaluated the extent to which these methodological differences can affect prevalence estimates of long COVID. In this study, we aimed to assess how symptom selection could impact prevalence rates of long COVID within a prospective cohort.

#### 72 Methods

73 RECoVERED is a prospective cohort of adults who experienced mild to critical COVID-19 [5]. 74 Methodology has been described in more detail elsewhere [5]. Briefly, study participants were 75 enrolled within 7 days of COVID-19 diagnosis (for community-dwelling participants) or 76 admission to hospital (for hospitalised participants). A small number of hospitalised 77 participants were enrolled retrospectively up to 3 months after illness onset in May and June 78 2020, to capture patients admitted to hospital during the first wave of COVID-19 in the 79 Netherlands. All participants had laboratory confirmation of SARS-CoV-2 infection by reverse 80 transcriptase polymerase chain reaction (RT-PCR). Individuals residing in a nursing home 81 and those with mental disorders deemed likely to interfere to adherence to study procedures 82 were excluded. Study participants were interviewed by trained study staff on the presence 83 and duration of 20 symptoms, socio-demographic details, and past medical history during the 84 first month of follow-up. On months 2 to 12 of follow-up, participants completed monthly 85 online surveys on the presence (in the past month) of these same symptoms; these questionnaires were repeated at month 18 and 24 of follow-up. 86 87 To demonstrate the effect of changing symptom-based definitions of long COVID, we 88 examined the proportion of individuals from month 3 since illness onset onwards who 89 reported at least 1 symptom among (1) any of the 20 recorded symptoms, (2) only symptoms 90 occurring within one month of COVID-19 onset, thus assumed to be attributable to COVID-91 19, (3) the four most commonly-reported long COVID symptoms (i.e., fatigue, dyspnoea, loss 92 of smell/taste, myalgia), and (4) the four long COVID symptoms that continued to be present 93 in at least 2 consecutive surveys (i.e., persistent symptoms). Corresponding 95% confidence 94 intervals (Cls) for each time-point were estimated according to the method for binomial 95 proportions[6].

96 RECoVERED was approved by the medical ethical review board of the Amsterdam
97 University Medical Centres (NL73759.018.20). For the current analysis, we used follow-up
98 data collected up to 1 June 2022.

#### 99 Results

100 Between 11 May 2020 and 21 June 2021, 349 participants were enrolled in RECoVERED, of 101 whom none were vaccinated for COVID-19 at enrolment. Of these participants, 292 102 (n=83.7%) completed at least 1 symptom survey. Those who did not complete any symptom 103 survey (n=57/349 [16.3%]) were excluded from the current analysis; they did not differ 104 significantly in age, sex, BMI or COVID-19 severity from those who completed at least one 105 survey. Over half of included participants were male (n=170/292, 58%) and the median age 106 was 51 years (interguartile range, IQR=36-62) (Table 1). Participants were followed for a 107 median of 562 days (IQR=399-689). However, median follow-up time was slightly shorter 108 among those who had had severe/critical disease (449 days, IQR=274-698) compared to 109 those with mild (561 days, IQR=412-658) and moderate (587 days, IQR=442-701) disease 110 (p=0.02).

111 Across all time-points, prevalence estimates were higher when adopting a more inclusive 112 selection of long COVID symptoms (Figure 1). The proportion of participants with long 113 COVID at month 3 since illness onset varied widely, from 56.0% (95%CI=48.9-62.9) when 114 restricting to persistent key long COVID symptoms to 81.2% (95%CI=74.9-86.2) when counting any of the 20 recorded symptoms. The difference between proportions was even 115 116 greater at month 12, ranging from 39.6% (95%CI=33.4-46.2) to 80.6% (95%CI=74.8-85.4). 117 When stratifying by acute COVID-19 severity, prevalence estimates of long COVID differed 118 most when defining long COVID according to persistent key long COVID symptoms 119 (Supplementary Figure S1). At 18 months after illness onset, the prevalence of long COVID 120 was 39.0% (95%CI=25.4-54.6) among those with severe/critical disease, 29.8 (95%CI=21.0-121 40.4) among those with moderate disease, and 21.5% (13.1-33.1) among participants with 122 mild COVID-19, defined according to persistent key long COVID symptoms.

#### 123 Discussion

124 Long COVID studies to date have differed in the number and type of symptoms considered 125 relevant. Selection of symptoms based on presumed underlying pathophysiology or 126 persistence over time remains a subjective process, making generalisability across studies 127 extremely challenging. We found that, even within the same cohort, the estimated prevalence 128 of long COVID at 12 months could differ by almost 60% according to the level of stringency 129 used to select symptoms. As expected, more restrictive methods resulted in a lower 130 proportion of participants being identified as having at least one symptom. We also observed 131 a lower prevalence when only participants with longitudinally persistent symptoms were 132 considered to have long COVID, thus excluding more fleeting symptom episodes. This is 133 likely to represent partly between-month relapsing-remitting pattern of symptoms in some 134 long COVID patients, and demonstrate that cross-sectional estimates may be biased towards higher prevalence due to including the transient presence of non-specific symptoms. 135 136 Our observations have important downstream consequences for prevention and intervention. 137 Firstly, particular symptoms may be correlated with specific risk factors. As a consequence, 138 symptom selection could affect a study's ability to identify these determinants. Moreover, 139 variation in symptom selection may have consequences for outcome measurement in clinical 140 trials for novel treatments for long COVID. If recovery is defined by the resolution of a 141 restricted list of symptoms, and this list varies between clinical trials, the probability of 142 achieving the outcome of interest may vary widely between studies. Indeed, disparities in 143 symptom selection when defining long COVID directly impacts the definition of what we 144 mean by recovery, adding further methodological complexity. Finally, wide variation in 145 estimating the prevalence of long COVID may introduce confusion among the general public 146 about the condition, and reinforce mistrust by parties who are sceptical about the 147 physiological nature of the condition[7]. These implications may, in turn, amplify stigma 148 towards individuals with long COVID, hinder access to care, and diminish investment in 149 further research.

150 Our study's strengths are the long follow-up time, prospective design, representation of the 151 full spectrum of COVID-19 disease severity, and comprehensive longitudinal symptom data. 152 This analysis also presents a novel perspective on the underlying methodology of a rapidly-153 growing evidence base on long COVID. However, our study also has limitations. Differential 154 loss-to-follow-up according to COVID-19 severity may have exerted a downward bias on 155 later prevalence estimates, with participants with severe/critical disease having a relatively 156 shorter follow-up time than those with mild or moderate COVID-19. Interestingly, however, 157 prevalence estimates appeared to increase slightly from month 11 after illness onset 158 onwards in all cross-sectional estimates. This can most likely be explained by residual 159 confounding of calendar time: those who were infected early on in the pandemic may have 160 had reduced access to the rapeutic interventions compared to those infected more recently. 161 When stratifying by acute COVID-19 severity, this effect seemed most pronounced in those 162 who had had mild or severe/critical disease, suggesting that clinical management for these 163 groups has changed more over time than among those with moderate disease 164 (Supplementary Figure S1). Finally, our symptom data was not complemented with 165 gualitative data; a mixed-methods approach may have shed further light on which symptoms 166 were directly associated with long COVID. 167 In conclusion, we have demonstrated the drastic variation in long COVID prevalence with 168 symptom-based definitions. Standardisation of the selection of long COVID symptoms is 169 therefore urgently needed. Harmonised data collection tools, as previously suggested [8], 170 could be one means to achieve greater comparability of results. Nevertheless, the vast range 171 of symptoms linked to the long COVID phenotype makes it difficult to balance 172 comprehensiveness with reproducibility – posing the risk of over-simplification of a complex 173 condition. Consensus from both patient and clinical societies, in combination with robust 174 qualitative data, is crucial to ensure that long COVID is defined in a standardised but 175 inclusive way.

176 Table 1. Socio-demographic, clinical and study characteristics of study participants of

the RECoVERED study, Amsterdam, the Netherlands, enrolled between May 2020

and June 2021 with at least one completed symptom survey, stratified by acute

# 179 COVID-19 severity

	Total	Mild	Moderate	Severe/ Critical	p-value			
	N=292	N=86	N=127	N=79				
Socio-demographic characteristics								
Sex								
Male	170 (58%)	44 (51%)	76 (60%)	50 (63%)				
Female	122 (42%)	42 (49%)	51 (40%)	29 (37%)				
Age, years	51.0 (36.0- 62.0)	41.0 (29.0- 54.0)	50.0 (34.0- 62.0)	60.0 (51.0- 66.0)	<0.001			
BMI, kg/m <sup>2</sup>	26.1 (23.3- 29.4)	24.4 (22.8- 27.3)	26.2 (23.5- 29.4)	27.4 (25.6- 33.4)	<0.001			
BMI category		-			<0.001			
Normal weight	120 (41%)	50 (58%)	52 (41%)	18 (23%)				
Overweight	101 (35%)	23 (27%)	45 (35%)	33 (42%)				
Obese	67 (23%)	12 (14%)	30 (24%)	25 (32%)				
Missing	4 (1%)	1 (1%)	0 (0%)	3 (4%)				
Country/region of birth					0.020			
Netherlands	182 (62%)	60 (70%)	79 (62%)	43 (54%)				
Morocco	8 (3%)	3 (3%)	2 (2%)	3 (4%)				
Asia, Middle East, Africa	29 (10%)	5 (6%)	14 (11%)	10 (13%)				
South America, Caribbean (including Suriname and Curacao)	40 (14%)	4 (5%)	18 (14%)	18 (23%)				
Other (Europe, Russia, Australia, Canada, USA, New Zealand)	22 (8%)	10 (12%)	9 (7%)	3 (4%)				
Missing	11 (4%)	4 (5%)	5 (4%)	2 (3%)				
Migration background					0.004			
Dutch	181 (62%)	61 (71%)	76 (60%)	44 (56%)				
Non-Dutch, OECD high-income	31 (11%)	11 (13%)	16 (13%)	4 (5%)				
Non-Dutch, OECD low/middle income	71 (24%)	10 (12%)	32 (25%)	29 (37%)				
Missing	9 (3%)	4 (5%)	3 (2%)	2 (3%)				
Smoking					0.12			
Non-smoker	181 (62%)	52 (60%)	73 (57%)	56 (71%)				
Smoker	19 (7%)	8 (9%)	10 (8%)	1 (1%)				
Ex-smoker	87 (30%)	23 (27%)	43 (34%)	21 (27%)				
Missing	5 (2%)	3 (3%)	1 (1%)	1 (1%)				
Highest level of education					<0.001			
None, primary or secondary education	41 (14%)	7 (8%)	22 (17%)	12 (15%)				
Vocational training	70 (24%)	9 (10%)	32 (25%)	29 (37%)				
University education	171 (59%)	66 (77%)	70 (55%)	35 (44%)				
Missing	10 (3%)	4 (5%)	3 (2%)	3 (4%)				
Number of COVID-19 high-risk comorbidities					<0.001			
0	160 (55%)	61 (71%)	75 (59%)	24 (30%)				
1	72 (25%)	18 (21%)	28 (22%)	26 (33%)				
2	36 (12%)	5 (6%)	16 (13%)	15 (19%)				
3 or more	24 (8%)	2 (2%)	8 (6%)	14 (18%)				
Cardiovascular disease	78 (27%)	11 (13%)	31 (24%)	36 (46%)	<0.001			
Diabetes	34 (12%)	5 (6%)	10 (8%)	19 (24%)	<0.001			
Chronic respiratory disease	19 (7%)	1 (1%)	8 (6%)	10 (13%)	0.011			
Cancer	16 (5%)	6 (7%)	6 (5%)	4 (5%)	0.76			
Immunosuppressed	5 (2%)	0 (0%)	2 (2%)	3 (4%)	0.17			
Psychiatric illness	18 (6%)	5 (6%)	9 (7%)	4 (5%)	0.83			

Other comorbidities	64 (22%)	11 (13%)	33 (26%)	20 (25%)	0.054			
	Total	Mild	Moderate	Severe/ Critical	p-value			
	N=292	N=86	N=127	N=79				
Clinical characteristics								
Symptom status at baseline					0.45			
Symptomatic	287 (98%)	85 (99%)	127 (100%)	75 (95%)				
Asymptomatic	2 (1%)	1 (1%)	0 (0%)	0 (0%)				
Missing	3 (1%)	0 (0%)	0 (0%)	4 (5%)				
Hospital admission	141 (48%)	4 (5%)	60 (47%)	77 (97%)	<0.001			
ICU admission	40 (14%)	NA	NA	40 (51%)	<0.001			
Days from illness onset to COVID-19 diagnosis	4 (2-10)	3 (1-8)	4 (2-11)	7 (2-11)	0.10			
Days from illness onset to hospitalisation	9 (7-14)	43 (9-85)	10 (8-16)	9 (7-12)	0.10			
Days from illness onset to ICU admission	10 (7-12)	NA	NA	10 (7-12)				
Received oxygen therapy before or during follow-up	135 (46%)	0 (0%)	59 (46%)	76 (96%)	<0.001			
Maximal HR, beats/min	82 (72-94)	75 (67-81)	84 (76-94)	94 (79-107)	<0.001			
Maximal RR, breaths/min	20 (16-24)	16 (16-16)	20 (20-24)	24 (20-32)	<0.001			
Lowest SpO <sub>2</sub> , %	96 (91-98)	98 (97-99)	96 (93-98)	88 (80-90)	<0.001			
Vaccinated during follow-up (primary					0.014			
series)								
Not vaccinated	40 (14%)	3 (3%)	23 (18%)	14 (18%)				
Vaccinated	222 (76%)	71 (83%)	95 (75%)	56 (71%)				
LTFU before vaccination	30 (10%)	12 (14%)	9 (7%)	9 (11%)				
Time from illness onset to first	247 (144-	197 (129-	247 (162-	373 (137-	0.006			
vaccination, days	364)	302)	318)	393)				
Died during follow-up	1 (0%)	0 (0%)	1 (1%)	0 (0%)	1.00			
	Study cha	aracteristics		1				
Place of recruitment			05 (540()	0 ( 10 ( )	<0.001			
Non-hospital	143 (49%)	75 (87%)	65 (51%)	3 (4%)				
	149 (51%)	11 (13%)	62 (49%)	76 (96%)				
lype of inclusion					<0.001			
Prospective	209 (72%)	73 (85%)	99 (78%)	37 (47%)				
Retrospective	83 (28%)	13 (15%)	28 (22%)	42 (53%)				
Days from illness onset to inclusion in study	12 (6-51)	7 (4-12)	12 (6-32)	42 (14-89)	<0.001			
Prospective inclusions only	9 (5-14)	6 (4-9)	9 (5-15)	14 (10-18)	<0.001			
Retrospective inclusions only	86 (75-95)	93 (73-96)	85 (80-92)	88 (74-97)	0.61			
Follow-up time from enrolment in study, days	562.0 (399.0- 689.0)	561.0 (412.0- 658.0)	587.0 (442.0- 701.0)	449.0 (274.0- 698.0)	0.020			
Lost to follow-up	77	24	25	28	NA			

180

181 BMI=Body mass index; HIC= high-income country; HR=heart rate; LMIC= low- or middle income

182 country; LTFU= Loss to follow-up; ICU= Intensive Care Unit; NA = Not applicable; OECD=

183 Organisation for Economic Co-operation and Development; PASC= Post-acute sequelae of COVID-

184 19; RR=respiratory rate; SpO<sub>2</sub> = oxygen saturation.

185 Continuous variables presented as median (IQR) and compared using the Kruskal-Wallis test;

186 categorical and binary variables presented as n (%) and compared using the Pearson  $\chi^2$  test (or 187 Fisher exact test if n<5).

Acute COVID-19 severity groups defined as: mild as having a RR <20/min and SpO2 on room air</li>
 >94% at both D0 and D7 study visits; moderate disease as having a RR 20-30/min, SpO2 90-94%
 and/or receiving oxygen therapy at D0 or D7; severe disease as having a RR> 30/min or SpO2 <90%</li>

191 at D0 or D7; critical disease as requiring ICU admission.

- BMI categories defined as: <25 kg/m<sup>2</sup> normal or underweight; 25-29 kg/m<sup>2</sup> overweight; ≥30 kg/m<sup>2</sup>
   obese.
- 194 Migration background was defined as Dutch and non-Dutch based on the country of birth of the
- 195 participant and their parents; those of non-Dutch background were further classified as originating
- 196 from a high-income (HIC) or low-/middle-income country (LMIC), according to the Organisation for
- 197 Economic Co-operation and Development (OECD).
- 198 High-risk COVID-19 comorbidities are defined as listed by the WHO Clinical Management Guidelines
- and include: cardiovascular disease (including hypertension), chronic pulmonary disease (excluding
- 200 asthma), renal disease, liver disease, cancer, immunosuppression (excluding HIV, including previous
- 201 organ transplantation), previous psychiatric illness and dementia.

Figure 1. Proportions over time of RECoVERED cohort participants (Amsterdam, the Netherlands) enrolled between 11 May 2020 and 21 June 2021 with long COVID, according to four different definitions with changing selection of symptoms



205

- Data presented above are from month 3 onwards, in line with the common definitions of long COVID.
   Subsequent selection of these symptoms was made according to the following criteria:
- 208 \* Any of the 20 symptoms included in the questionnaire
- \*\* COVID-19 symptoms, including only those symptoms with a reported start date within the first
   month of overall COVID-19 onset
- \*\*\* Counting only the four most commonly-reported long COVID symptoms in our cohort: fatigue,
   dyspnoea, loss of smell/taste and myalgia
- 213 \*\*\*\* Counting only the four most commonly-reported long COVID symptoms in our cohort if they had
- 214 persisted since illness onset (i.e., individuals with a later relapse in any of these four symptoms were 215 no longer included in the numerator)

216 217	Refer	ences: WHO. A clinical case definition of post COVID-19 condition by a Delphi consensus.
218		World Health Organization (WHO) clinical case definition working group on post
219		COVID-19 condition 2021.
220	2.	(NICE) NIfHCE. COVID-19 rapid guideline: managing the long-term effects of COVID-
221		19 NG188 Vol. 2021: NICE, <b>2021</b> .
222	3.	Blomberg B, Mohn KG-I, Brokstad KA, et al. Long COVID in a prospective cohort of
223		home-isolated patients. Nature Medicine 2021; 27(9): 1607-13.
224	4.	Tran V-T, Porcher R, Pane I, Ravaud P. Course of post COVID-19 disease symptoms
225		over time in the ComPaRe long COVID prospective e-cohort. Nature
226		Communications <b>2022</b> ; 13(1): 1812.
227	5.	Wynberg E, van Willigen HDG, Dijkstra M, et al. Evolution of Coronavirus Disease
228		2019 (COVID-19) Symptoms During the First 12 Months After Illness Onset. Clinical
229		Infectious Diseases 2021.
230	6.	Dean N, Pagano M. Evaluating Confidence Interval Methods for Binomial Proportions
231		in Clustered Surveys. Journal of Survey Statistics and Methodology 2015; 3(4): 484-
232		503.
233	7.	Rubin R. As Their Numbers Grow, COVID-19 "Long Haulers" Stump Experts. JAMA
234		<b>2020</b> ; 324(14): 1381-3.
235	8.	Sigfrid L, Cevik M, Jesudason E, et al. What is the recovery rate and risk of long-term
236		consequences following a diagnosis of COVID-19? A harmonised, global longitudinal
237		observational study protocol. BMJ Open <b>2021</b> ; 11(3): e043887.

# 238 Statements & Declarations

#### 239 Acknowledgements:

- 240 This research letter was prepared on behalf of the RECoVERED Study Group:
- 241 At the Public Health Service of Amsterdam: Ivette Agard, Jane Ayal, Floor Cavdar, Marianne
- 242 Craanen, Udi Davinovich, Annemarieke Deuring, Annelies van Dijk, Ertan Ersan, Laura del
- 243 Grande, Joost Hartman, Nelleke Koedoot, Romy Lebbink, Dominique Loomans, Agata
- 244 Makowska, Tom du Maine, Ilja de Man, Amy Matser, Lizenka van der Meij, Maria Oud,
- 245 Marleen van Polanen, Clark Reid, Leeann Storey, Marc van Wijk.
- 246 At the Amsterdam University Medical Centres: Joost van den Aardweg, Joyce van Assem,
- 247 Marijne van Beek, Thyra Blankert, Maartje Dijkstra, Orlane Figaroa, Leah Frenkel, Marit van
- 248 Gils, Jelle van Haga, Xiaochuan (Alvin) Han, Agnes Harskamp-Holwerda, Mette Hazenberg,
- 249 Soemeja Hidad, Anja Lok, Nina de Jong, Hans Knoop, Neeltje Kootstra, Lara Kuijt, Eric Moll-
- 250 van Charante, Pythia Nieuwkerk, Colin Russell, Karlijn van der Straten, Annelou van der
- 251 Veen, Bas Verkaik, Gerben-Rienk Visser.

## 252 Funding:

- 253 This publication is part of the project RECoVERED with project number 10150062010002 of
- the research programme Infectieziektebestrijding 3 2019-2023, which is financed by the
- 255 Netherlands Organisation for Health Research and Development (ZonMw) and awarded to
- 256 M.D. de Jong. This work was additionally supported by the Public Health Service of
- 257 Amsterdam (Research & Development grant numbers 21-14 and 22-09), awarded to M.

258 Prins.

#### 259 Author contributions:

- 260 Conceptualisation: Maria Prins, Anders Boyd, Tjalling Leenstra, Godelieve de Bree, Elke
- 261 Wynberg. Data collection: Anouk Verveen, Hugo van Willigen, Elke Wynberg. Formal
- analysis and investigation: Anders Boyd, Elke Wynberg. Writing original draft: Maria Prins,
- Anders Boyd, Elke Wynberg. Writing review and editing: All authors. Funding acquisition:

- 264 Maria Prins, Godelieve de Bree, Menno de Jong. Supervision and project management:
- 265 Maria Prins, Godelieve de Bree, Menno de Jong, Tjalling Leenstra.
- 266 Potential Conflicts of Interest:
- 267 The authors declare no conflicts of interests in terms of relationships or activities. The
- funding source had no influence on study design. All authors had access to the study data.
- 269 Ethical Approval and Patient Consent Statement:
- 270 RECoVERED is an observation study that was approved by the medical ethical review board
- of the Amsterdam University Medical Centres (NL73759.018.20). All participants of the
- 272 RECoVERED study provided written informed consent.

